Citadel Advisors
BOLD

Citadel Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Citadel Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,017,783
Closed -$38.2M – 10132
2019
Q3 		$28.6M Buy
1,017,783
+346,020
+52% +$11.8M 0.01% 1167
2019
Q2 		$25.4M Buy
671,763
+322,398
+92% +$12.4M 0.01% 1203
2019
Q1 		$13.6M Sell
349,365
-714,485
-67% -$20.5M 0.01% 1703
2018
Q4 		$22.7M Buy
1,063,850
+522,154
+96% +$13.5M 0.01% 1131
2018
Q3 		$21.4M Buy
541,696
+137,021
+34% +$5.11M 0.01% 1336
2018
Q2 		$15.5M Buy
+404,675
New +$15M 0.01% 1535
2018
Q1 		– Sell
-339,588
Closed -$11.5M – 9056
2017
Q4 		$10.6M Buy
339,588
+228,667
+206% +$6.28M 0.01% 1679
2017
Q3 		$3.11M Buy
110,921
+100,663
+981% +$2.19M ﹤0.01% 2870
2017
Q2 		$196K Sell
10,258
-557
-5% -$8.9K ﹤0.01% 6590
2017
Q1 		$184K Buy
+10,815
New +$175K ﹤0.01% 6584

Citadel Advisors's BOLD Position: Q4 2019 in Review

Citadel Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 1,017,783 shares — an estimated $38.2M sold.

Citadel Advisors first reported a position in BOLD in Q1 2017 and held it in 10 quarters. The position peaked at $28.6M in Q3 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Citadel Advisors reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Citadel Advisors sold 1,017,783 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $38.2M.
  • Citadel Advisors first reported a position in Audentes Therapeutics, Inc in Q1 2017 and held it in 10 quarters.
  • Citadel Advisors's Audentes Therapeutics, Inc position peaked at $28.6M in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.